NasdaqGS - Delayed Quote USD

Standard BioTools Inc. (LAB)

1.0800

+0.0200

+(1.89%)

At close: June 9 at 4:00:01 PM EDT

1.0508

-0.03

(-2.70%)

After hours: June 9 at 6:08:38 PM EDT

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical developmentSOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and i

GlobeNewswire 10 days ago

LAB
+1.89%
Standard BioTools First Quarter 2025 Earnings: Beats Expectations

Standard BioTools ( NASDAQ:LAB ) First Quarter 2025 Results Key Financial Results Revenue: US$40.8m (down 10% from 1Q...

Simply Wall St. last month

LAB
+1.89%
Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a 10% revenue decline, Standard BioTools Inc (LAB) showcases resilience with improved cost management and a strong cash position.

GuruFocus.com last month

LAB
+1.89%
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) delivered earnings and revenue surprises of 0% and 1.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

LAB
+1.89%
Standard BioTools Reports First Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 mil

GlobeNewswire last month

LAB
+1.89%
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming Ameri

GlobeNewswire last month

LAB
+1.89%
Sight Sciences Appoints Gary Burbach to its Board of Directors

MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company’s Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. “

GlobeNewswire last month

BWXT

LAB
+1.89%

SGHT
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of

GlobeNewswire last month

LAB
+1.89%
Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know

It's been a mediocre week for Standard BioTools Inc. ( NASDAQ:LAB ) shareholders, with the stock dropping 18% to...

Simply Wall St. 3 months ago

LAB
+1.89%
Standard BioTools to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual Healthcare Conference - March 3rd – 5th, 2025 Presenting on Monday, March 3, 2025, at 3:10 p.m. ET2025 Leerink Partners Global Healthcare Conference - March 9th – 12th, 2025Participating in investor meetings on March 12thKeyBanc’s 5th Annual Healthcare Forum – March 18th & 19th, 2

GlobeNewswire 3 months ago

LAB
+1.89%
Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Despite a decline in overall revenue, Standard BioTools Inc (LAB) showcases resilience with cost reductions, strategic partnerships, and a robust cash position.

GuruFocus.com 3 months ago

LAB
+1.89%
Standard BioTools: Q4 Earnings Snapshot

The South San Francisco, California-based company said it had a loss of 9 cents per share. Losses, adjusted for stock option expense and amortization costs, came to 5 cents per share. The company that makes equipment to control fluids posted revenue of $46.7 million in the period.

Associated Press Finance 3 months ago

LAB
+1.89%
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million

GlobeNewswire 3 months ago

LAB
+1.89%
Shareholders in Standard BioTools (NASDAQ:LAB) have lost 66%, as stock drops 10.0% this past week

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...

Simply Wall St. 3 months ago

LAB
+1.89%
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412)

GlobeNewswire 3 months ago

LAB
+1.89%
Strength Seen in American Well (AMWL): Can Its 18.8% Jump Turn into More Strength?

American Well (AMWL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 4 months ago

AMWL

LAB
+1.89%
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024. Standard BioTools expects fourth quarter 2024 revenue of appro

GlobeNewswire 4 months ago

LAB
+1.89%
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trialsSOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of Nature Medicine titled “Proteomic changes upon treatment with s

GlobeNewswire 4 months ago

LAB
+1.89%
In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$56m market cap drop, institutional owners may be forced to take severe actions

Key Insights Given the large stake in the stock by institutions, Standard BioTools' stock price might be vulnerable to...

Simply Wall St. 5 months ago

LAB
+1.89%

Performance Overview

Return	LAB	S&P 500 (^GSPC)
YTD	-38.29%	+2.11%
1-Year	-53.45%	+12.32%
3-Year	-44.04%	+49.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Standard BioTools Inc. (LAB)

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

Standard BioTools First Quarter 2025 Earnings: Beats Expectations

Standard BioTools Inc (LAB) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools Reports First Quarter 2025 Financial Results

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Sight Sciences Appoints Gary Burbach to its Board of Directors

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Standard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Standard BioTools to Participate in Upcoming Investor Conferences

Standard BioTools Inc (LAB) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Standard BioTools: Q4 Earnings Snapshot

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Shareholders in Standard BioTools (NASDAQ:LAB) have lost 66%, as stock drops 10.0% this past week

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Strength Seen in American Well (AMWL): Can Its 18.8% Jump Turn into More Strength?

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$56m market cap drop, institutional owners may be forced to take severe actions

Performance Overview